Filamin A Interacting Protein 1-Like (FILIP1L) (Middle Region) Peptide
FILIP1L
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN976860
150,78 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination:
France
Envoi sous 15 à 22 jours ouvrables
Aperçu rapide pour Filamin A Interacting Protein 1-Like (FILIP1L) (Middle Region) Peptide (ABIN976860)
Antigène
FIL1L (FILIP1L)
(Filamin A Interacting Protein 1-Like (FILIP1L))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-FILIP1L antibody (Catalog #: ARP52360_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- FIL1L (FILIP1L) (Filamin A Interacting Protein 1-Like (FILIP1L))
-
Sujet
-
FILIP1L acts as a regulator of the antiangiogenic activity on endothelial cells. When overexpressed in endothelial cells, FILIP1L leads to inhibition of cell proliferation and migration and an increase in apoptosis. FILIP1L inhibits melanoma growth when e
Alias Symbols: DOC-1, DOC1, GIP90, GIP130, GIP130a, GIP130b, GIP130c
Protein Size: 893 -
Poids moléculaire
- 102 kDa
-
ID gène
- 11259
-
NCBI Accession
- NM_014890, NP_055705
-
UniProt
- Q4L180
Antigène
-
Vous êtes ici:
